清脆的
免疫原性
噬菌体
病毒学
大流行
生物
2019年冠状病毒病(COVID-19)
病毒载体
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
计算生物学
重组DNA
医学
传染病(医学专业)
免疫学
遗传学
基因
免疫系统
疾病
病理
大肠杆菌
作者
Jingen Zhu,Neeti Ananthaswamy,Swati Jain,Himanshu Batra,Wei-Chun Tang,Venigalla B. Rao
出处
期刊:Methods in molecular biology
日期:2021-12-17
卷期号:: 209-228
被引量:7
标识
DOI:10.1007/978-1-0716-1884-4_10
摘要
The COVID-19 pandemic brought to the fore the urgent need for vaccine design and delivery platforms that can be rapidly deployed for manufacture and distribution. Though the mRNA and adenoviral vector platforms have been enormously successful to control SARS-CoV-2 viral infections, it is unclear if this could be replicated against more complex pathogens or the emerging variants. Recently, we described a "universal" platform that can incorporate multiple vaccine targets into the same nanoparticle scaffold by CRISPR engineering of bacteriophage T4. A T4-COVID vaccine designed with this technology elicited broad immunogenicity and complete protection against virus challenge in a mouse model. Here, we describe the detailed methodology to generate recombinant bacteriophage T4 backbones using CRISPR that can also be broadly applicable to other bacteriophages that abundantly pervade the Earth.
科研通智能强力驱动
Strongly Powered by AbleSci AI